| Title |
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
|
|---|---|
| Published in |
Journal of Hematology & Oncology, June 2016
|
| DOI | 10.1186/s13045-016-0283-0 |
| Pubmed ID | |
| Authors |
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang |
| Abstract |
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 29% |
| Unknown | 5 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 199 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 198 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 41 | 21% |
| Researcher | 25 | 13% |
| Student > Ph. D. Student | 16 | 8% |
| Student > Master | 16 | 8% |
| Other | 12 | 6% |
| Other | 27 | 14% |
| Unknown | 62 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 40 | 20% |
| Medicine and Dentistry | 40 | 20% |
| Agricultural and Biological Sciences | 17 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Immunology and Microbiology | 8 | 4% |
| Other | 21 | 11% |
| Unknown | 63 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 85. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2024.
All research outputs
#510,162
of 25,738,558 outputs
Outputs from Journal of Hematology & Oncology
#27
of 1,302 outputs
Outputs of similar age
#10,065
of 368,168 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 16 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,302 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 368,168 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.